Reflecting on 2022 and Looking Ahead to 2023

It’s hard to believe that another year has come and gone, and as we look back on the past year at DNALabs, we have a lot to be proud of.

One of our biggest accomplishments in 2022 was the opening of our new US operations in Boca Raton, Florida. This expansion has allowed us to better serve our clients in the US and has laid the foundation for further growth in the coming years.

We also had a significant milestone with the launch of our first public stock offering. This was a major step forward for DNALabs and has allowed us to further invest in research and development, as well as expand our reach and impact.

In addition to these accomplishments, we’ve also welcomed on board a number of new clients and have undertaken several exciting new research projects. It’s been a busy and rewarding year for the DNALabs team.

Looking ahead to 2023, we have a number of exciting products in the pipeline. One of the most anticipated is our brain health panel, which includes a concussion section. This innovative test will provide valuable insights for athletes, coaches, and healthcare professionals, helping to improve diagnosis and treatment of concussion-related injuries.

We’re also excited to continue expanding our reach into the US and global markets. As a leader in the genetic testing market, we’re committed to bringing our best-in-class pharmacogenomics tests and lifestyle genetic tests to a wider audience.

As the CEO of DNALabs, I see our company becoming a global leader in the industry. We’re constantly striving to push the boundaries of what’s possible and to provide our clients with the most accurate and comprehensive genetic testing available.

We’re grateful for all of the support we’ve received this past year and we look forward to continuing to make a positive impact in the coming years. Thank you for being a part of the DNALabs journey!

Moni Lustig,
Chief Executive Officer
DNALabs

Questions for our CEO about investment opportunities? Book a call here.